Initial trial of an electronic dashboard to improve dosing of hydroxychloroquine within the VA healthcare system: Time series analysis (Preprint)

Author:

Montgomery AnnaORCID,Tarasovsky Gary,Izadi ZaraORCID,Shiboski StephenORCID,Whooley MaryORCID,Dana Jo,Ehiorobo Iziegbe,Barton JenniferORCID,Bennett LoriORCID,Chung LorindaORCID,Reiter KimberlyORCID,Wahl ElizabethORCID,Subash MeeraORCID,Schmajuk GabrielaORCID

Abstract

BACKGROUND

Hydroxychloroquine (HCQ) is commonly used for patients with autoimmune conditions. Long term use of HCQ can cause retinal toxicity, but this risk can be reduced if high doses are avoided.

OBJECTIVE

We developed and piloted an EHR-based dashboard to improve safe prescribing of HCQ within the Veterans Health Administration (VHA). We observed pilot facilities over a one-year period to determine whether they were able to improve the proportion of patients receiving inappropriate doses of HCQ.

METHODS

Patients receiving HCQ were identified from the VHA Corporate Data Warehouse. Using PowerBI (Microsoft), we constructed a dashboard to display patient identifiers and most recent HCQ dose and weight (flagged if ≥ 5.2mg/kg/day). Six VHA pilot facilities were enlisted to test the dashboard and invited to participate in monthly webinars. We performed an interrupted time-series analysis using synthetic controls to assess changes in the proportion of patients receiving HCQ ≥ 5.2mg/kg/day between October 2020 to November 2021.

RESULTS

We identified 18,190 total users of HCQ nationwide in the VHA, including 1,276 patients at the 6 pilot facilities. Nationwide at baseline, 20.6% of patients were receiving high doses of HCQ. We observed significant improvements in the proportion of HCQ prescribed at doses ≥ 5.2mg/kg/day among pilot facilities after the dashboard was deployed (-0.06, 95% CI (-0.08, -0.04)). The difference in the post-intervention linear trend for pilot vs. synthetic controls was also significant (-0.06, 95%CI (-0.08, -0.05)).

CONCLUSIONS

Use of an EHR-based dashboard reduced the proportion of patients receiving higher than recommended doses of HCQ and significantly improved performance at six VHA facilities. National roll-out of the dashboard will enable further improvements in safe prescribing of HCQ.

CLINICALTRIAL

Publisher

JMIR Publications Inc.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3